Antibodies News and Research

RSS

UT Southwestern awarded $763,000 as grant to expand studies of Peregrine's anti-PS antibodies

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has awarded a two-year, $763,000 grant to Philip Thorpe, Ph.D., of the University of Texas Southwestern Medical Center for research expanding its studies of anti-phosphatidylserine (anti-PS) antibodies as potential treatments for viral hemorrhagic fever (VHF) infections.

26 Aug 2009

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that study results demonstrated that arimoclomol exhibited both statistically significant neuroprotective and neuroregenerative effects in brain cells of animals induced with stroke, offering important insights into this drug candidate’s mechanism of action.

25 Aug 2009

Tripep and Cosmix AG license RAS and mRNA Display Library technologies

Tripep and the German biotech company Cosmix AG have both licensed their respective technologies (RAS and mRNA Display Library) to a newly formed US company named Opsonic Therapeuticals Inc. within which Tripep’s RAS technology will be developed.

25 Aug 2009

NIAID to establish a human immune profiling research consortium in 2010; invites grant applications

The National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, is accepting grant applications for a new initiative to establish a consortium of human immune profiling research centers.

25 Aug 2009

Lpath achieves one of the four Phase 1 objectives by demonstrating its optimized fermentation process

Lpath, Inc., the category leader in lipidomics-based therapeutics, demonstrated commercially acceptable yields in its optimized fermentation process. In doing so, Lpath achieved one of four Phase 1 objectives established by Merck Serono, the exclusive worldwide licensee of ASONEP and Lpath's development partner, and will receive a milestone payment according to the terms of the Merck Serono license agreement.

25 Aug 2009

Thyretain TSI Reporter BioAssay test for detecting auto-antibodies attains the FDA clearance

Diagnostic HYBRIDS announces the FDA clearance, for marketing under the 510(k) pre-notification process, of the Thyretain TSI Reporter BioAssay. Thyretain is an in vitro diagnostic use test that specifically detects auto-antibodies called thyroid stimulating immunoglobulins (TSI) in patient serum.

25 Aug 2009

Research reveals that diarrheal bacteria can cause colon cancers

Johns Hopkins scientists say they have figured out how bacteria that cause diarrhea may also be the culprit in some colon cancers. The investigators say that strains of the common Bacteroides fragilis (ETBF) dupe immune system cells into permitting runaway colon tissue inflammation, a precursor for malignant growth.

24 Aug 2009

Discovery of genetic biomarkers enable targeted personalised medication for Colorectal cancer

Colorectal cancer (CRC) is the second leading cause of cancer-related death in the Western world. Fortunately physicians today have an abundance of drug therapies available to improve survival length for more advanced cancer patients. Now the discovery of genetic biomarkers relevant to CRC means that targeted personalised medication is increasingly common.

24 Aug 2009

Research study discovers lethal effects of tetracycline and chloramphenicol against certain bacterial strains

By studying the intricate mechanisms at work in protein production, a Princeton-led team has discovered why certain kinds of antibiotics are so effective. In doing so, they also have discovered how one protein protects against cell death, shedding light on a natural cancer-fighting process.

21 Aug 2009

New strategy found to increase the efficacy of protein-based drugs

A new method for attaching a large protective polymer molecule to a protein appears to improve protein drugs significantly.

20 Aug 2009

FDA approves Hiberix Haemophilus influenzae type b vaccine

In response to a U.S. shortage of a vaccine to protect infants from Haemophilus influenzae type b (Hib), GlaxoSmithKline (NYSE: GSK) has received accelerated approval from the FDA (Food and Drug Administration) for Hiberix((R)) [Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)] as a booster dose in children 15 months through four years of age. Hib is an often severe and potentially deadly bacterial infection that can cause meningitis.

19 Aug 2009

Research study highlights the biological importance of Vitamin D in humans and other primates

A new study has concluded that one key part of the immune system, the ability of vitamin D to regulate anti-bactericidal proteins, is so important that is has been conserved through almost 60 million years of evolution and is shared only by primates, including humans - but no other known animal species.

19 Aug 2009

New understanding on meningitis cause

A specific protein on the surface of a common bacterial pathogen allows the bacteria to leave the bloodstream and enter the brain, initiating the deadly infection known as meningitis. The new finding, which may guide development of improved vaccines to protect those most vulnerable, including young infants and the elderly, is now available online in the Journal of Experimental Medicine.

19 Aug 2009

Tiny magnetic particles guide stem cells to damaged tissue

Microscopic magnetic particles have been used to bring stem cells to sites of cardiovascular injury in a new method designed to increase the capacity of cells to repair damaged tissue, UCL scientists announced today.

18 Aug 2009

Scientists harness carbon nanomaterials for drug delivery, oxygen sensors

Two nanoscale devices recently reported by University of Pittsburgh researchers in two separate journals harness the potential of carbon nanomaterials to enhance technologies for drug or imaging agent delivery and energy storage systems, in one case, and, in the other, bolster the sensitivity of oxygen sensors essential in confined settings, from mines to spacecrafts.

17 Aug 2009

Mother's immune system may block fetal treatments for blood diseases

Pediatric researchers have resolved an apparent contradiction in the field of prenatal cell transplantation - a medical approach that holds future promise in correcting sickle cell disease and other serious congenital blood disorders. In a new study in animals, the researchers showed that the mother's immune response interferes with the offspring's earlier ability to tolerate transplanted donor cells.

17 Aug 2009

Research on blood transfusions points to a potential risk of transfusing donated platelets

Doctors have noticed a pattern in performing bone marrow transplants as a cure for diseases involving bone marrow failure: more transfusions before a bone marrow transplant correlates with a higher likelihood of rejection, says James Zimring, MD, PhD, assistant professor of pathology and laboratory medicine at Emory University School of Medicine.

12 Aug 2009

New insights into identifying children at risk for autoimmune brain disorders

A new study by researchers at Columbia University Mailman School of Public Health's Center for Infection and Immunity indicates that pediatric obsessive-compulsive disorder (OCD), Tourette syndrome and/or tic disorder may develop from an inappropriate immune response to the bacteria causing common throat infections.

11 Aug 2009

Seattle Genetics reaches milestone under collaboration agreement with MedImmune

Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration agreement with MedImmune, LLC, a wholly owned subsidiary of AstraZeneca. The milestone was triggered by MedImmune’s initiation of a phase I clinical trial of MEDI-547, its anti-EphA2 ADC for solid tumors.

11 Aug 2009

Researchers launch study into search-and-destroy antigen for deadly skin cancer

UT Southwestern Medical Center researchers are studying a new antigen to see whether it can track down and kill cancer cells in patients with recurring melanoma, the leading cause of skin cancer deaths.

11 Aug 2009

Antibodies News and Research

UT Southwestern awarded $763,000 as grant to expand studies of Peregrine's anti-PS antibodies

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

Tripep and Cosmix AG license RAS and mRNA Display Library technologies

NIAID to establish a human immune profiling research consortium in 2010; invites grant applications

Lpath achieves one of the four Phase 1 objectives by demonstrating its optimized fermentation process

Thyretain TSI Reporter BioAssay test for detecting auto-antibodies attains the FDA clearance

Research reveals that diarrheal bacteria can cause colon cancers

Discovery of genetic biomarkers enable targeted personalised medication for Colorectal cancer

Research study discovers lethal effects of tetracycline and chloramphenicol against certain bacterial strains

New strategy found to increase the efficacy of protein-based drugs

FDA approves Hiberix Haemophilus influenzae type b vaccine

Research study highlights the biological importance of Vitamin D in humans and other primates

New understanding on meningitis cause

Tiny magnetic particles guide stem cells to damaged tissue

Scientists harness carbon nanomaterials for drug delivery, oxygen sensors

Mother's immune system may block fetal treatments for blood diseases

Research on blood transfusions points to a potential risk of transfusing donated platelets

New insights into identifying children at risk for autoimmune brain disorders

Seattle Genetics reaches milestone under collaboration agreement with MedImmune

Researchers launch study into search-and-destroy antigen for deadly skin cancer

Immunology eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery